Mainstream

Day One Biopharmaceuticals outlines $140M–$150M 2025 OJEMDA revenue target as new patient scripts accelerate

Day One Biopharmaceuticals outlines $140M–$150M 2025 OJEMDA revenue target as new patient scripts accelerate

Post ContentdawnRead More

You might also be interested in reading DeFi may be ‘quietly re-rating’ given outperformance against Bitcoin: Bitwise.

August 6, 2025
In Mainstream